Search
Grandsun: Future Approval and Launch of GST-HG131 for Hepatitis B Treatment Remain Uncertain
1 week ago /
Read about 0 minute
Author：小编
Grandsun has revealed that its innovative hepatitis B treatment drug, GST-HG131, is being considered for inclusion in the breakthrough therapy category and is currently undergoing a public announcement phase, which entails the risk of non-approval. The development of this drug has involved an extensive research and development cycle, necessitating substantial investment. Furthermore, clinical trials are inherently susceptible to numerous variables, which could result in outcomes that fall short of expectations or even lead to failure. Consequently, there exists a degree of uncertainty surrounding the potential approval and subsequent launch of GST-HG131 in the future.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
